Yahoo Finance22d
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...
WebMD22d
FDA Approves Omvoh for Crohn’s Disease
Jan. 16, 2025 – The FDA has approved the drug Omvoh for treating adults with moderately to severely active Crohn's disease, a type of chronic inflammatory bowel disease. This marks the second ...
Hosted on MSN21d
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat moderately to severely active Crohn's disease in the adult population.
Morningstar22d
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
View the Omvoh brand logo. About the VIVID Clinical Trial Program VIVID-1 is a randomized, double-blind, placebo-controlled 52-week study. Patients received mirikizumab 900mg by intravenous (IV ...